Patients with advanced pancreatic cancer are beginning to receive daraxonrasib, a daily oral medication targeting the KRAS genetic mutation. As families navigate the FDA’s compassionate use program and clinical trials admit participants, the treatment offers a new therapeutic avenue for a malignancy with historically low survival rates.
Russell Reed’s Push for Daraxonrasib at Memorial Cancer Institute
Russell Reed spent nearly two months in an exhaustive effort to obtain daraxonrasib for his stage 4 pancreatic cancer, according to local reporting from Florida. After the cancer metastasized to his liver late last year, his oncologist, Jesus C. Fabregas, identified him as a candidate for the experimental targeted therapy.
The treatment became accessible through the Food and Drug Administration’s Expanded Access Program, commonly known as compassionate use, after the agency announced its availability on May 1. To secure the medication, Reed’s care team made weekly calls to the manufacturer and the FDA while his wife, Marnie, led a public advocacy campaign that included social media videos and participation in Pancreatic Cancer Action Network events. Representative Brian Mast also intervened to help secure a direct call from the FDA.
Reed received his first dose on July 3 at the Memorial Cancer Institute in Hollywood, becoming one of the first patients in South Florida to access the medication. Revolution Medicines, the drug developer, has distributed daraxonrasib to approximately 500 patients across nearly all 50 states, though a formal waitlist total remains unquantified by company spokesperson Brianne Cannon.
Clinical Trials and the Shift in KRAS Targeting
The development of treatments like daraxonrasib marks a shift in oncology. For years, the KRAS genetic mutation—which drives the majority of pancreatic tumors—was widely considered undruggable. Clinical evaluations, including work at the Huntsman Cancer Institute, have begun testing daily oral medications designed to inhibit these specific genetic drivers in metastatic patients.
For Russ, who started taking the medication in February 2025, the daily regimen involves regular toxicity monitoring. While managing side effects such as weakness and gastrointestinal issues, patients undergo regular CT scans and bi-weekly clinical visits. In Russ’s case, monitoring showed that his tumor markers remained largely unchanged for months, slowing the disease’s progression.
Early Trials for High-Risk Preventive Vaccines
While targeted therapies treat advanced diagnoses, researchers are also exploring prevention. Investigators at the Kimmel Cancer Center and the Skip Viragh Pancreatic Cancer Center at Johns Hopkins University completed a Phase 1 trial evaluating an experimental peptide-based vaccine known as mKRAS-VAX, according to scientific publications in Cancer Discovery.
The study enrolled 20 participants with inherited predispositions to pancreatic cancer and identifiable pancreatic abnormalities between April 2022 and February 2026. Over 13 weeks, participants received four doses of the vaccine, which targets the six most common KRAS mutations associated with pancreatic malignancies. According to data highlighted by health journalism outlets, 90% of participants developed significant immune responses, registering an average 18.2-fold increase in mutant KRAS-specific T-cell activity.
After a median follow-up period of 16.5 months, no participants in the Phase 1 trial developed pancreatic cancer or high-risk lesions requiring surgery. Researchers emphasized that the study was designed primarily to assess safety and immunogenicity rather than clinical efficacy, noting that mild-to-moderate adverse effects like fatigue and flu-like symptoms were common among recipients.
Worth a look